Transl Oncol 2021 Jul 28;14(10):101186. Epub 2021 Jul 28.
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan; Research division, RIN Institute Inc, 2-5-10, Shintomi, Chuo-Ku, Tokyo, 104-0041, Japan; Department of Immune Medicine, National Cancer Center Research Institute, National Cancer Center, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan. Electronic address:
TMEM180, a novel colon cancer-specific protein with a 12-transmembrane topology, is upregulated at low oxygen. Previously, we established a humanized monoclonal antibody against TMEM180 aimed at clinical trials. Prior to such trials, it is necessary to clarify the function of TMEM180 in cancer. Read More